Comparative Efficiency and Safety of Pharmacological Approaches to the Management of Obesity

Hainer, Vojtěch

doi:10.2337/dc11-s255

Cited by 11 publications

(7 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pharmacological treatment of obesity should ensure a long-term sustainable weight loss, possibly positively influence metabolic disorders that cause the development of obesity [7,8]. The aim of the work is to show effectiveness of orlistat and phentermine in outpatient obesity management and to emphasize that pharmacotherapy for obesity is an integral part of the complex therapy of this serious disease.…”

Section: Introductionmentioning

confidence: 99%

Orlistat and Phentermine in Weight Loss in Selected Czech Population

Pavlík¹,

Fajfrová²,

Horáček³

et al. 2016

Mil. Med. Sci. Lett.

View full text Add to dashboard Cite

SummaryAim: To describe effectiveness of orlistat and phentermine in soldiers of the Armed Forces of the Czech Republic.Methods: In ambulatory patients, some anthropometric and biochemical parameters were compared before administration with 120 mg of orlistat three times a day or 15 mg of phentermine once a day. The same parameters were compared after a three-month therapy. This group included 289 patients (238 males and 51 females) who were administered the same dose of orlistat or phentermine for the entire period of time.Results: Statistically significant weight loss in both genders, on average by 4.6 ± 4.2 kg in males and by 5.3 ± 4.3 kg in females, was observed in patients taking orlistat within three months. Statistically significant weight loss, on average by 6.5 ± 6.0 kg in males and by 5.2 ± 4.3 kg in females, was also observed in patients taking phentermine for the same period of time. As for monitored biochemical parameters, a decrease of total cholesterol, HDL cholesterol and glucose at a statistically significant level (p<0.05) was observed in the group of females, the same statistically significant decrease, but in triglycerides, was proved in the group of males. Then a decrease of total cholesterol and increase of HDL cholesterol at a statistically significant level (p<0.001) was observed in the group of males.Conclusion: We can state that in our patients we have proven a positive effect of orlistat or phentermine substitution on their weight reduction.

show abstract

Section: Introductionmentioning

confidence: 99%

Orlistat and Phentermine in Weight Loss in Selected Czech Population

Pavlík¹,

Fajfrová²,

Horáček³

et al. 2016

Mil. Med. Sci. Lett.

View full text Add to dashboard Cite

show abstract

“…These differences have also important implications for lifestyle intervention (nutrition and exercise) and drug therapy. The dramatic increase in the prevalence of overweight and obesity, affecting more than 1.1 billion individuals worldwide, has resulted in a major burden on healthcare resources in developed countries (Field et al 2009;Hainer 2011). Excess fat mass increases the risk of mortality overall and increases individually the risk of chronic diseases like type 2 diabetes, hypertension, cardiovascular disease, stroke, osteoarthritis, obstructive sleep apnoea and certain cancers with sex-specific differences Kautzky-Willer and Handisurya 2009).…”

Section: Obesitymentioning

confidence: 99%

“…Anti-obesity drugs can act through different mechanisms: via suppression of food intake in the central nervous system or by decreasing gut absorption of food and/or by increasing energy expenditure, thermogenesis or oxidation of nutrients (Hainer 2011). Drugs reducing food intake act primarily on neurotransmitters of the central nervous system and include noradrenergic drugs, serotonergic drugs, serotonergic and adrenergic drugs, drugs binding to the cannabinoid receptors and others.…”

Section: Drug Therapy For Obesitymentioning

confidence: 99%

“…Drugs reducing food intake act primarily on neurotransmitters of the central nervous system and include noradrenergic drugs, serotonergic drugs, serotonergic and adrenergic drugs, drugs binding to the cannabinoid receptors and others. The efficacy of anti-obesity drugs should be validated by reduction of fat stores (Table 1), in particular visceral adipose tissue, maintenance of weight loss, reduction of obesity-related health risks and mortality and improvement of quality of life (Hainer 2011). Treatment should be effective and safe and individually tailored considering age, sex and presence of co-morbidities including careful assessment of the risk/ No information is provided regarding potential sex differences in cardiovascular events in humans Women report more weight-related psychosocial problems.…”

Section: Drug Therapy For Obesitymentioning

confidence: 99%

See 1 more Smart Citation

Obesity and Diabetes

Kautzky‐Willer

Lemmens‐Gruber

2012

Sex and Gender Differences in Pharmacology

View full text Add to dashboard Cite

“…Moreover, the European Drug Agency suspended the decision on the registration of sibutramine in the whole of Europe based on the outcomes of SCOUT study (Sibutramine Cardiovascular Outcomes) in January 2010 [5,6]. For this reason an anti-obesity drug containing orlistat is the only standard anti-obesity drug in the Czech market [7,8]. The aim of modern pharmacotherapy of obesity is to help the patients to reduce their weight and to maintain it on a long-term basis or to treat the metabolic disorders which predispose the individual to develop obesity [9][10][11].…”

Section: Introductionmentioning

confidence: 99%